ERBB2 and breast carcinoma: While studies such as that by Nagayama et al. [19] are invaluable to our understanding of anti-HER2 therapies in treating breast cancer, no study has yet been carried out to specifically investigate the vast body of publicy available evidence on originator trastuzumab and how this evidence has changed over time.